연구동향 분석

Fecal Calprotectin and Phenotype Severity in Patients with Cystic Fibrosis: A Systematic Review and Meta-Analysis

Saeedeh Talebi Andrew S. Day Majid Khadem Rezaiyan Golnaz Ranjbar Mitra Zarei Mahammad Safarian Hamid Reza Kianifar 2022년

논문상세정보
인용/피인용
' Fecal Calprotectin and Phenotype Severity in Patients with Cystic Fibrosis: A Systematic Review and Meta-Analysis' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Calprotectin
  • Exocrine pancreatic insufficiency
  • Inflammation
  • cysticfibrosis
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
649 0

0.0%

' Fecal Calprotectin and Phenotype Severity in Patients with Cystic Fibrosis: A Systematic Review and Meta-Analysis' 의 참고문헌

  • The lung and gut microbiome : what has to be taken into consideration for cystic fibrosis?
  • The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses
    Melsen WG [2014]
  • The concentration of calprotectin in the stools of children with diagnosed cystic fibrosis
    Więcek S [2017]
  • Severe disease in Cystic Fibrosis and fecal calprotectin levels
    Parisi GF [2017]
  • ROBINS-I : a tool for assessing risk of bias in nonrandomised studies of interventions
    Sterne JA [2016]
  • Protein processing and inflammatory signaling in cystic fibrosis : challenges and therapeutic strategies
    Belcher CN [2010]
  • Preferred reporting items for systematic reviews and meta-analyses : the PRISMA statement
    Moher D [2010]
  • Potential of anti-inflammatory treatment for cystic fibrosis lung disease
  • Intestinal inflammation in cystic fibrosis
    Briars G [2001]
  • Intestinal inflammation and impact on growth in children with cystic fibrosis
    Dhaliwal J [2015]
  • Inflammation in cystic fibrosis lung disease : pathogenesis and therapy
  • Inflammation in cystic fibrosis : an update
    Roesch EA [2018]
  • Improved residual fat malabsorption and growth in children with cystic fibrosis treated with a novel oral structured lipid supplement : a randomized controlled trial
  • Host-microorganism interactions in lung diseases
    Marsland BJ [2014]
  • Gut microbiota in children with cystic fibrosis : a taxonomic and functional dysbiosis
    Coffey MJ [2019]
  • Gastrointestinal manifestations of cystic fibrosis
    Sabharwal S [2016]
  • Fecal calprotectin in cystic fibrosis and its relation to disease parameters : a longitudinal analysis for 12 years
  • Evidence of intestinal inflammation in patients with cystic fibrosis
    Werlin SL [2010]
  • Evidence for a cystic fibrosis enteropathy
  • Enteropathy – a new finding in cystic fibrosis
    Werlin S [2008]
  • Effect of probiotics on respiratory, gastrointestinal and nutritional outcomes in patients with cystic fibrosis : a systematic review
    Anderson JL [2017]
  • Distribution of macrophages and granulocytes expressing L1 protein(calprotectin)in human Peyer’s patches compared with normal ileal lamina propria and mesenteric lymph nodes
    Bjerke K [1993]
  • Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with Lactobacillus GG : a randomised clinical trial
    Bruzzese E [2014]
  • Decreased fecal calprotectin levels in cystic fibrosis patients after antibiotic treatment for respiratory exacerbation
    Schnapp Z [2019]
  • Cystic fibrosis-a multiorgan protein misfolding disease
  • Cystic fibrosis : insight into CFTR pathophysiology and pharmacotherapy
    Lubamba B [2012]
  • Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
    Stang , A. [2010]
  • Correlation of intestinal lactulose permeability with exocrine pancreatic dysfunction
    Mack DR [1992]
  • Calprotectin in cystic fibrosis
    Rumman N [2014]
  • Bacterial overgrowth, dysbiosis, inflammation, and dysmotility in the Cystic Fibrosis intestine
    Dorsey J [2017]
  • Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine
    Norkina O [2004]
  • Associations between gut microbial colonization in early life and respiratory outcomes in cystic fibrosis
    Hoen AG [2015]
  • Altered intestinal microbiota composition, antibiotic therapy and intestinal inflammation in children and adolescents with cystic fibrosis
  • Age-related levels of fecal M2-pyruvate kinase in children with cystic fibrosis and healthy children 0 to 10years old
    Garg M [2018]
  • Age-dependent variation of fecal calprotectin in cystic fibrosis and healthy children
    Garg M [2017]